tiprankstipranks
Zymeworks Advances Biotherapeutic Pipeline in 2024
Company Announcements

Zymeworks Advances Biotherapeutic Pipeline in 2024

Don't Miss our Black Friday Offers:

Zymeworks ( (ZYME) ) has issued an announcement.

Zymeworks Inc. has made significant strides in 2024, marking pivotal advancements in their biotherapeutic pipeline. Key highlights include dosing the first patient in a Phase 1 trial of ZW171 for MSLN-expressing cancers and presenting promising preclinical data on ADC candidates ZW220 and ZW251. Their partner, Jazz Pharmaceuticals, has submitted a New Drug Application for zanidatamab, a HER2-targeting antibody, potentially leading to a U.S. approval for biliary tract cancer. With a robust cash position of $374.9 million, Zymeworks is strategically expanding its focus on innovative therapies, aiming for long-term growth and transformative patient care.

Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskZymeworks to Showcase Innovations at Investor Conferences
TipRanks Canadian Auto-Generated NewsdeskZymeworks Secures FDA Approval for Ziihera
TheFlyZymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App